clinical trial · NCT02158858
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Constellation Pharmaceuticals·phase2·completed·n = 336
MyelofibrosisLeukemia, Myelocytic, AcuteMyelodysplastic/Myeloproliferative NeoplasmMyelodysplastic Syndrome (MDS)PreleukemiaPrimary MyelofibrosisMyeloproliferative DisordersBone Marrow DiseasePelabresibRuxolitinib
brief summary
Phase 1 Part: Open-label, sequential dose escalation study of pelabresib (CPI-0610) in patients with previously treated Acute Leukemia, Myelodysplastic/Myeloproliferative Neoplasms, and Phase 2 Part: Open-label study of pelabresib (CPI-0610) with and without Ruxolitinib in patients with Myeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia). Pelabresib (CPI-0610) is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
started
Jul 16, 2014
primary completion
Jan 9, 2025
completion
Jan 9, 2025
last updated
Oct 8, 2025
official title
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol